Back to Rankings

DNLI

Denali TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
AVLAYAH approval and launch validate Denali's BBB TransportVehicle platform, the company says first commercial patients are already on therapy, and the balance sheet still shows $1.05 billion in cash, cash equivalents, and marketable securities with runway through at least the next 12 months.[#SEC-8K-2026-05-07][#10-Q-2026-05-07]
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.6.
What can break
AVLAYAH is still an early launch; payer penetration, patient starts, distribution, and manufacturing scale-up remain execution risks.[#SEC-8K-2026-05-07]
Momentum
79
Value
41
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $23.50 · Bull $35.00 · Bear $11.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-10 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $34.25
Why
Momentum79 · Δ7d +1.6
Value41 · Δ7d -0.1
Sentiment46 · Δ7d +6.6
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
+1.2
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
46
34% active weight
Current posture
7d trendImproving
Δ7d
+6.6
Δ21d
+7.6
Why this grade

Composite grade C. Momentum 78.8 / Value 41.1 / Sentiment 45.8

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$3.7B
Beta
1.02
Shares Out
158.71M
P/E (TTM) · Derived
-7.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.85
Rev YoY
-100.0%
EPS YoY
-11.4%
Gross Margin
-570.7%
Op Margin
-37938.0%
Net Debt
-$825.59M
Current Ratio
9.28
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology